Clinical trials: Sirolimus, completed
Hemangioma, Kaposiform Hemangioendothelioma
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
to evaluate the safety and efficacy of Low-dose sirolimus in Kaposiform Hemangioendothelioma in Chinese children by a prospective, randomized open trial.
- Trial name
- NCT04077515
- Testing
- Sirolimus(0.8mg/m2), Sirolimus(0.7mg/m2)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Children's Hospital of Fudan University
Retroperitoneal Fibrosis
Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis
Retroperitoneal fibrosis refers to a group of diseases characterized by hyperplasia of the fibrosclerotic tissues in the retroperitoneal space, which can compress the surrounding ureters and inferior vena cava and cause serious…
- Trial name
- NCT04047576
- Testing
- Sirolimus, Corticosteroid
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University International Hospital
Renal Cell Carcinoma
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer.
- Trial name
- NCT00563147
- Testing
- tivozanib (AV-951) plus temsirolimus
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Coronary Heart Disease
Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)
The purpose of this study is to evaluate whether adding estradiol to rapamycin better prevents coronary artery reblockage after drug-eluting stent implantation.
- Trial name
- NCT00402636
- Testing
- rapamycin plus 17beta estradiolvalerat-eluting stent, rapamycin-eluting stent
- Where
- 2 sites in Germany
- Volunteers
- 502 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Bladder Cancer
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
The purpose of this study is to test the safety of gemcitabine applied to the bladder directly combined with different oral doses of everolimus and to assess the right doses. Gemcitabine will be given at a fixed dose.
- Trial name
- NCT01259063
- Testing
- Everolimus and Intravesical Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
This phase I trial studies the side effects and the best dose of everolimus when given together with bendamustine hydrochloride in treating patients with cancer of the blood (hematologic cancer) that has returned after a period…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT02240719
- Testing
- everolimus, bendamustine hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, Davis
Cardiovascular Abnormalities
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the lymphatic-vascular organisations.
- Trial name
- vasca-LM (NCT01811667)
- Testing
- Sirolimus
- Where
- Belgium
- Volunteers
- 19 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Coronary Artery Disease, Coronary Artery Stenosis
ReZolve2 Clinical Investigation
The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.
- Trial name
- RESTORE II (NCT01845311)
- Testing
- ReZolve2 Scaffold
- Where
- 3 sites in Australia, Brazil and 1 more
- Volunteers
- 89 people
- Sponsor
- REVA Medical, Inc.
Organ Transplantation, Renal Transplantation
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
The purpose of this study is to evaluate the safety and efficacy of everolimus in combination with basiliximab, and steroids with and without cyclosporine microemulsion in de novo kidney transplant recipients.
- Trial name
- CERTES02 (NCT00154284)
- Testing
- Everolimus (Certican), Cyclosporine (Neoral), Steroid
- Volunteers
- 114 people
- Sponsor
- Novartis
Neuroendocrine Tumors
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)
This record combines the results of CRAD001K24133 and CRAD001K24133E1. The purpose of the CRAD001K24133 study was to evaluate the safety profile of everolimus in patients with advanced neuroendocrine tumors of pancreatic origin…
- Trial name
- NCT01595009
- Testing
- Everolimus (RAD001)
- Where
- 11 sites in Germany
- Volunteers
- 246 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer
Sirolimus and Cetuximab in Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of sirolimus and cetuximab that can be given to patients with advanced cancer.
- Trial name
- NCT00940381
- Testing
- Sirolimus, Cetuximab
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- PTK/RAD (NCT00303732)
- Testing
- RAD001 (everolimus), PTK787 (vatalanib)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Daniel George, MD
Urothelial Carcinoma, Bladder Cancer
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment.
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
- Trial name
- NCT02788201
- Testing
- 75 approved agents, COXEN
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Artery Disease
Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)
The FANTOM I pilot study is intended to assess safety of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
- Trial name
- FANTOM I (NCT02512003)
- Testing
- Fantom Scaffold
- Where
- 2 sites in Brazil, Poland
- Volunteers
- 7 people
- Sponsor
- REVA Medical, Inc.
Healthy
Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fed conditions.
- Trial name
- NCT02296762
- Testing
- Sirolimus
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Adult Diffuse Astrocytoma, Adult Mixed Glioma
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood…
- Conditions
- Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Subependymal Giant Cell Astrocytoma
- Trial name
- NCT00823459
- Testing
- Everolimus, Archival Tissue Analysis
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Susan Chang
Renal Transplantation
ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
The study is designed to evaluate whether the initiation of everolimus together with the reduction or discontinuation of calcineurin inhibitors (CNIs) will improve graft function in the maintenance of renal transplant recipients…
- Trial name
- NCT00170846
- Testing
- Everolimus (RAD001), Calcineurin Inhibitors (CNI), Mycophenolate acid (MPA)/Azathioprine (AZA)
- Where
- Switzerland
- Volunteers
- 394 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
BIBF 1120 and RAD001 in Solid Tumors - Phase I
BIBF1120 and RAD001 in solid tumors
- Trial name
- BARIS (NCT01349296)
- Testing
- Everolimus + BIBF 1120
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- University of Cologne
Lung Cancer
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Gefitinib and everolimus may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving gefitinib together with everolimus may kill more tumor cells.
- Trial name
- NCT00096486
- Testing
- everolimus, gefitinib
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
The objective of this investigation is to determine the following items in all patients receiving Torisel for a certain period after marketing: 1. Confirmation of efficacy and safety for medical practice use. 2.
- Trial name
- NCT01210482
- Testing
- Temsirolimus
- Where
- Japan
- Volunteers
- 1,050 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.